Cases & Deals

Share

BioMarin acquires Alesta Therapeutics

August 2026

Client(s) BioMarin Pharmaceutical Inc.

Jones Day is advising BioMarin Pharmaceutical Inc. in the acquisition of Alesta Therapeutics B.V. for $275 million in upfront cash consideration, plus up to $215 million in contingent milestone payments. Immediately prior to the closing of this transaction, Alesta will spin out all of its non-ALE 1 assets to a newly formed entity.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.